Christopher Johnson
Sourced from institutional research profiles (UAMS TRI or ARA).
Associate Professor
Pharmacy Practice, College of Pharmacy
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Christopher Johnson's research interests encompass a broad range of biological and medical topics, as evidenced by his diverse publication record. His work has contributed to understanding genetic sequencing, including the zebrafish reference genome and human chromosomes 20 and 6. He has also investigated metabolic processes, such as splanchnic lipolysis in human obesity, and has published on the role of Integrative and Conjugative Elements (ICEs) in biological systems. Further research areas include CD8 T cell function and the epidemiology of renal stones.
Johnson's publication history spans several decades, indicating sustained engagement with scientific inquiry. His scholarship metrics, including an h-index of 50, 155 total publications, and over 14,000 citations, reflect a significant body of work. He has collaborated with researchers at the University of Arkansas for Medical Sciences, including Laura E. Gressler, Jacob T. Painter, and M Shrikhande.
His active lab website suggests ongoing research activities. Johnson is recognized as recently active in research, with his most recent publication in 2024.
Metrics
- h-index: 50
- Publications: 155
- Citations: 14,110
Positions
-
Associate Principal Scientist 2016–presentRecursion (United States) Biology ORCID
-
Associate ProfessorUniversity of Arkansas for Medical Sciences Pharmacy Practice, College of Pharmacy Institutional directory
-
Postdoctoral associate 2011–2016Massachusetts Institute of Technology Biology ORCID
-
Graduate Research Assistant 2006–2011University of Minnesota Microbiology ORCID
-
Research Assistant 2002–2006University of Minnesota Lab Medicine and Pathology ORCID
-
Research Assistant 1996–1998US Department of Veterans Affairs ORCID
Selected Publications
-
EE490 Utilization and Costs of Patients With Type-2 Diabetes and Cardiovascular Disease Treated With Sodium Glucose Cotransporter-2 Inhibitors and Glucagon Like Peptide-1 Receptor Agonists (2024)
Collaboration Network
Top Collaborators
- EE490 Utilization and Costs of Patients With Type-2 Diabetes and Cardiovascular Disease Treated With Sodium Glucose Cotransporter-2 Inhibitors and Glucagon Like Peptide-1 Receptor Agonists
- EE490 Utilization and Costs of Patients With Type-2 Diabetes and Cardiovascular Disease Treated With Sodium Glucose Cotransporter-2 Inhibitors and Glucagon Like Peptide-1 Receptor Agonists
- EE490 Utilization and Costs of Patients With Type-2 Diabetes and Cardiovascular Disease Treated With Sodium Glucose Cotransporter-2 Inhibitors and Glucagon Like Peptide-1 Receptor Agonists
- EE490 Utilization and Costs of Patients With Type-2 Diabetes and Cardiovascular Disease Treated With Sodium Glucose Cotransporter-2 Inhibitors and Glucagon Like Peptide-1 Receptor Agonists
Similar Researchers
Based on overlapping research topics